Case Studies

Acutus Medical, Inc’s (NASDAQ: AFIB) CEO David Roman recently spoke with Wall Street Analyzer to provide an overview of the company, discuss recent news, and go over key goals for the next 6-8 months. The company is focused on the treatment of atrial fibrillation and other cardiac arrhythmias and has a novel mapping system that enables physicians to visualize disease on a patient by patient basis and therefore has a higher success rate than current standard of care procedures. Mr. Roman went over AFIB’s recent Q3 results that included an over 50% increase in their international procedures and a 17% year to year growth in overall procedures. Perhaps the biggest announcement was the company’s deal with Medtronic for sale of their access portfolio, referred to as Left Heart Access (LHA), and consists of uncapped revenue based earn-outs for four years after the official launch. Acutus Medical produced $17.3 million in revenue in 2021. […]

About Co-Diagnostics, Inc: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection […]